Socinski, M A <br/><br/>
Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Sep 2013 
 - 2390-6 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdt235  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Albumins--adverse effects<br/>Antineoplastic Agents, Phytogenic--adverse effects<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Carboplatin--adverse effects<br/>Carcinoma, Large Cell--drug therapy<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm Metastasis--drug therapy<br/>Neoplasms, Squamous Cell--drug therapy<br/>Organoplatinum Compounds--adverse effects<br/>Paclitaxel--adverse effects<br/>Survival<br/>Survival Rate<br/>Treatment Outcome